$SGHT
Sight Sciences, Inc.

2021 Q3 Form 10-Q Financial Statement

#000095017021001384 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $13.10M $12.54M $3.502M
YoY Change 51.44% 257.94% -41.34%
Cost Of Revenue $2.062M $2.305M $2.085M
YoY Change -21.3% 10.55% 6.38%
Gross Profit $11.04M $10.23M $1.417M
YoY Change 83.04% 621.95% -64.75%
Gross Profit Margin 84.26% 81.61% 40.46%
Selling, General & Admin $20.79M $17.76M $7.664M
YoY Change 85.16% 131.73% -13.69%
% of Gross Profit 188.33% 173.61% 540.86%
Research & Development $4.279M $3.546M $1.443M
YoY Change 98.29% 145.74% -29.61%
% of Gross Profit 38.76% 34.66% 101.83%
Depreciation & Amortization $200.0K $200.0K $200.0K
YoY Change 100.0% 0.0%
% of Gross Profit 1.81% 1.96% 14.11%
Operating Expenses $25.07M $21.31M $9.107M
YoY Change 87.28% 133.95% -16.6%
Operating Profit -$14.03M -$11.08M -$7.690M
YoY Change 90.75% 44.03% 11.45%
Interest Expense $1.122M $1.082M $549.0K
YoY Change 108.55% 97.09% -216.81%
% of Operating Profit
Other Income/Expense, Net -$2.001M -$5.435M -$73.00K
YoY Change 915.74% 7345.21%
Pretax Income -$17.15M -$17.59M -$8.310M
YoY Change 112.05% 111.71% 12.75%
Income Tax $16.00K $22.00K $6.000K
% Of Pretax Income
Net Earnings -$17.17M -$17.62M -$8.316M
YoY Change 112.04% 111.82% 12.68%
Net Earnings / Revenue -131.05% -140.53% -237.46%
Basic Earnings Per Share -$0.43
Diluted Earnings Per Share -$430.8K -$372.7K -$184.6K
COMMON SHARES
Basic Shares Outstanding 47.27M
Diluted Shares Outstanding 39.85M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $271.5M $35.57M
YoY Change
Cash & Equivalents $271.5M $35.57M $35.75M
Short-Term Investments
Other Short-Term Assets $4.493M $2.359M
YoY Change
Inventory $2.948M $2.576M
Prepaid Expenses
Receivables $8.920M $6.887M
Other Receivables $0.00 $0.00
Total Short-Term Assets $287.8M $47.39M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.420M $1.418M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $182.0K $3.467M
YoY Change
Total Long-Term Assets $3.214M $5.116M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $287.8M $47.39M
Total Long-Term Assets $3.214M $5.116M
Total Assets $291.1M $52.51M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.839M $3.224M
YoY Change
Accrued Expenses $2.569M $3.919M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $10.32M $12.06M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $32.49M $32.30M
YoY Change
Other Long-Term Liabilities $2.273M $8.105M
YoY Change
Total Long-Term Liabilities $34.76M $40.41M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.32M $12.06M
Total Long-Term Liabilities $34.76M $40.41M
Total Liabilities $45.07M $52.47M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$137.1M -$119.9M
YoY Change
Common Stock $383.0M $2.607M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $246.0M -$117.3M -$72.04M
YoY Change
Total Liabilities & Shareholders Equity $291.1M $52.51M
YoY Change

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$17.17M -$17.62M -$8.316M
YoY Change 112.04% 111.82% 12.68%
Depreciation, Depletion And Amortization $200.0K $200.0K $200.0K
YoY Change 100.0% 0.0%
Cash From Operating Activities -$16.51M -$12.44M -$15.01M
YoY Change -17.14%
INVESTING ACTIVITIES
Capital Expenditures -$287.0K -$265.0K -$532.0K
YoY Change -50.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$287.0K -$265.0K -$532.0K
YoY Change -50.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 252.7M -54.00K 30.05M
YoY Change -100.18%
NET CHANGE
Cash From Operating Activities -16.51M -12.44M -15.01M
Cash From Investing Activities -287.0K -265.0K -532.0K
Cash From Financing Activities 252.7M -54.00K 30.05M
Net Change In Cash 235.9M -12.76M 14.51M
YoY Change -187.9%
FREE CASH FLOW
Cash From Operating Activities -$16.51M -$12.44M -$15.01M
Capital Expenditures -$287.0K -$265.0K -$532.0K
Free Cash Flow -$16.22M -$12.17M -$14.48M
YoY Change -15.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001531177
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
518000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3467000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
386000
CY2021Q2 us-gaap Assets
Assets
52510000
CY2020Q4 us-gaap Assets
Assets
72806000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3224000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40587
dei Entity Registrant Name
EntityRegistrantName
SIGHT SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
80-0625749
dei Entity Address Address Line1
EntityAddressAddressLine1
4040 Campbell Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
877
dei Local Phone Number
LocalPhoneNumber
266-1144
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
SGHT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47265164
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35572000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61511000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6887000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5363000
CY2021Q2 us-gaap Inventory Net
InventoryNet
2576000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2598000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2359000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1161000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
47394000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
70633000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1418000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1269000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
231000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2158000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4083000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4070000
CY2021Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4754000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1183000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119896000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90041000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-117289000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3086000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12061000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9314000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
32302000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
31955000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8105000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3055000
CY2021Q2 us-gaap Liabilities
Liabilities
52468000
CY2020Q4 us-gaap Liabilities
Liabilities
44324000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21831000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21831000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9732032
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9732032
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9509182
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9509182
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
9000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2598000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-88849000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52510000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72806000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12535000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3502000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21170000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9998000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2305000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2085000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4606000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4213000
CY2021Q2 us-gaap Gross Profit
GrossProfit
10230000
CY2020Q2 us-gaap Gross Profit
GrossProfit
1417000
us-gaap Gross Profit
GrossProfit
16564000
us-gaap Gross Profit
GrossProfit
5785000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3546000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1443000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6986000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3843000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17760000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7664000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32310000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18342000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
21306000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
9107000
us-gaap Operating Expenses
OperatingExpenses
39296000
us-gaap Operating Expenses
OperatingExpenses
22185000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11076000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7690000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22732000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16400000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1082000
CY2020Q2 us-gaap Interest Expense
InterestExpense
549000
us-gaap Interest Expense
InterestExpense
2166000
us-gaap Interest Expense
InterestExpense
1101000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5435000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-73000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4883000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17593000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8310000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29781000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17454000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
74000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
37000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17615000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8316000
us-gaap Net Income Loss
NetIncomeLoss
-29855000
us-gaap Net Income Loss
NetIncomeLoss
-17491000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.85
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9610408
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9457893
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9564096
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9453640
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-88849000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
277000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12240000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-100801000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
196000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
931000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17615000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-117289000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-54683000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
61000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9175000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-63796000
CY2020Q2 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
0
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
65000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8316000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-72040000
us-gaap Profit Loss
ProfitLoss
-29855000
us-gaap Profit Loss
ProfitLoss
-17491000
us-gaap Depreciation
Depreciation
289000
us-gaap Depreciation
Depreciation
288000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
346000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
280000
us-gaap Share Based Compensation
ShareBasedCompensation
1208000
us-gaap Share Based Compensation
ShareBasedCompensation
126000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
104000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
229000
us-gaap Inventory Write Down
InventoryWriteDown
276000
us-gaap Inventory Write Down
InventoryWriteDown
841000
sght Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
310000
sght Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
270000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4872000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-19000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-74000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-74000
sght Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
2246000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1628000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-880000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
255000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1138000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1197000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
288000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3081000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1438000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
752000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
13000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-311000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1594000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2288000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
186000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
456000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25306000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15009000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
369000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
532000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-369000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-532000
sght Payments Of Stock Issuance Costs Related To Initial Public Offering
PaymentsOfStockIssuanceCostsRelatedToInitialPublicOffering
471000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
30150000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
106000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
207000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-264000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30052000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25939000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14511000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61511000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21237000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35572000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35748000
us-gaap Interest Paid Net
InterestPaidNet
1548000
us-gaap Interest Paid Net
InterestPaidNet
623000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
181000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
66000
sght Noncash Or Part Noncash Unpaid Offering Costs In Accounts Payable And Accrued Liabilities
NoncashOrPartNoncashUnpaidOfferingCostsInAccountsPayableAndAccruedLiabilities
2764000
sght Noncash Or Part Noncash Unpaid Offering Costs In Accounts Payable And Accrued Liabilities
NoncashOrPartNoncashUnpaidOfferingCostsInAccountsPayableAndAccruedLiabilities
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(35,31,32,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 1. Company and Nature of Business</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(35,31,32,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of Business</span></p><p style="margin-left:56.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sight Sciences, Inc. (the “Company”) was incorporated in the state of Delaware in 2010. The Company is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company’s surgical glaucoma product portfolio features the OMNI Surgical System, a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. The Company’s nonsurgical dry eye product portfolio consists of the TearCare System ("TearCare") for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids.</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is located and headquartered in Menlo Park, California. The Company also operates an office in Southlake, Texas.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Split</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 7, 2021 the Company effected a 2-for-1 stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable convertible preferred stock.</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this stock split and adjustment of the redeemable convertible preferred stock conversion ratios.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 19, 2021, the Company closed its initial public offering (“IPO”) of its common stock in which the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock, and sold an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,500,000</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock upon the full exercise of the underwriters’ option to purchase additional shares at $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.00</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, raising approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">253.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in proceeds, net of underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and estimated offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were incurred as of June 30, 2021.</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immediately prior to the closing of the IPO, all then-outstanding shares of redeemable convertible preferred stock were converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,534,404</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. Further, all outstanding redeemable convertible preferred stock warrants were converted into warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">659,028</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (see Note 9). The condensed consolidated financial statements as of June 30, 2021, including share and per share amounts, do not give effect to the IPO or the conversion of the convertible preferred stock into common stock, as the IPO and such conversions were completed subsequent to June 30, 2021.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(35,31,32,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Significant Risks and Uncertainties</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception, the Company has incurred losses and negative cash flows from operations. As of June 30, 2021, the Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and recorded a net loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the six months then ended and expects to incur future additional losses. If the Company’s revenue levels from its products are not sufficient or if the Company is unable to secure additional funding when desired, the Company may need to delay the development of its products and scale back its business and operations.</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company believes that its existing sources of liquidity will satisfy its working capital and capital requirements for at least 12 months from the issuance of its financial statements. Failure to generate sufficient revenues, achieve planned gross margins, or control operating costs will require the Company to raise additional capital through equity or debt financing. Such additional financing may not be available on acceptable terms, or at all, and could require the Company to modify, delay, or abandon some of its planned future expansion or expenditures or reduce some of its ongoing operating costs, which could harm its business, operating results, financial condition, and ability to achieve its intended business objectives.</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (“COVID-19”) outbreak a global pandemic recommending containment measures worldwide. On March 16, 2020 the Company implemented alternative work arrangements for its employees and limited its employees’ travel activities to protect its employees and to comply with the provisions described within the local shelter in place order. Certain U.S. federal, state and local governmental authorities issued other orders and directives, including restrictions on elective procedures and therapies, aimed at minimizing the spread of COVID-19. As such, the COVID-19 pandemic impacted and is expected to continue to impact demand for the Company’s products, which are used in procedures and therapies that are considered elective. Although some of the governmental restrictions have since been lifted or scaled back, recent and future surges of COVID-19, including recent surges in the delta variant of COVID-19, may result in restrictions being re-implemented in response to efforts to reduce the spread of COVID-19.</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the COVID-19 outbreak (including prevalence and effect of the delta variant and other potential COVID-19 variants), the status of health and safety actions taken to contain its spread and any additional preventative and protective actions that governments, or the Company, may direct, any resurgence of COVID-19 that may occur and how quickly and to what extent economic and operating conditions normalize within the markets in which the Company operates. The COVID-19 pandemic could disrupt the operations of the Company’s third-party manufacturers and other suppliers. Although the Company has not experienced disruptions in its supply chain to date, it cannot predict how long the pandemic and measures intended to contain the spread of COVID-19 will continue and what effect COVID-19 and the associated containment measures will have on our suppliers and vendors, in particular for any of the Company’s suppliers and vendors that may not qualify as essential businesses and suffer more significant disruptions to their business operations. The Company is working closely with its manufacturing partners and suppliers to help ensure the Company is able to source key components and maintain appropriate inventory levels to meet customer demand.</span></p>
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119900000
us-gaap Net Income Loss
NetIncomeLoss
-29900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(35,31,32,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expense during the reporting period. The most significant estimates related to inventory excess and obsolescence, the selection of useful lives of property and equipment, determination of the fair value of stock option grants, the fair value of the redeemable convertible preferred stock warrants, and provisions for income taxes and contingencies. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the financial statements. Actual results could differ from these estimates and such differences could be material to the Company’s financial position and results of operations.</span></p>
CY2021Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3300000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
400000
us-gaap Depreciation
Depreciation
300000
CY2020Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
300000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2337000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2012000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
919000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
743000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1418000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1269000
CY2021Q2 us-gaap Depreciation
Depreciation
200000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3919000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1971000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
395000
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
267000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
274000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
456000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
446000
CY2021Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4754000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
3086000
CY2021Q2 sght Redeemable Preferred Stock Warrants Liabilities Non Current
RedeemablePreferredStockWarrantsLiabilitiesNonCurrent
6984000
CY2020Q4 sght Redeemable Preferred Stock Warrants Liabilities Non Current
RedeemablePreferredStockWarrantsLiabilitiesNonCurrent
2112000
CY2021Q2 sght Interest Payable Non Current
InterestPayableNonCurrent
651000
CY2020Q4 sght Interest Payable Non Current
InterestPayableNonCurrent
465000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
125000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
134000
CY2021Q2 sght Other Non Current Liabilities
OtherNonCurrentLiabilities
345000
CY2020Q4 sght Other Non Current Liabilities
OtherNonCurrentLiabilities
344000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8105000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3055000
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2698000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3045000
CY2021Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
32302000
CY2020Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
31955000
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
32302000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
31955000
CY2021Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.164
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y10M24D
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1944000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
11667000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
11667000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
9722000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
35000000
CY2019Q3 us-gaap Area Of Land
AreaOfLand
10823
CY2019Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
178000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
138000
us-gaap Operating Lease Expense
OperatingLeaseExpense
353000
us-gaap Operating Lease Expense
OperatingLeaseExpense
313000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
176000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
172000
us-gaap Operating Lease Payments
OperatingLeasePayments
353000
us-gaap Operating Lease Payments
OperatingLeasePayments
344000
CY2021Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
23000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
23000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
96000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
440000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
85000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
66000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
73000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
68000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
29000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
29000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
283000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
603000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
46000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
74000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
237000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
529000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
18656000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9732032
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9732032
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
395000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
125000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
134000
sght Temporary Equity Dividends
TemporaryEquityDividends
0
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
each share of redeemable convertible preferred stock converts into two shares of common stock.
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21831000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
sght Common Stock Vote For Each Share
CommonStockVoteForEachShare
1
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
31620028
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29782878
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
240860
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
451670
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
451670
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3137776
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.94
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
25600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2060000
sght Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
2339000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2339000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.56
sght Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod
68190
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
68190
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.21
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
222850
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.94
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
240860
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5185736
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39934000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1841606
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.75
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18337000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5155736
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
39625000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9610408
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
931000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
65000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1208000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
126000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17615000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8316000
us-gaap Net Income Loss
NetIncomeLoss
-29855000
us-gaap Net Income Loss
NetIncomeLoss
-17491000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9457893
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9564096
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9453640
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.85
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12535000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3502000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21170000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9998000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2305000
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2085000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4606000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4213000
CY2021Q2 us-gaap Gross Profit
GrossProfit
10230000
CY2020Q2 us-gaap Gross Profit
GrossProfit
1417000
us-gaap Gross Profit
GrossProfit
16564000
us-gaap Gross Profit
GrossProfit
5785000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
21306000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
9107000
us-gaap Operating Expenses
OperatingExpenses
39296000
us-gaap Operating Expenses
OperatingExpenses
22185000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11076000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7690000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22732000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16400000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1082000
CY2020Q2 us-gaap Interest Expense
InterestExpense
549000
us-gaap Interest Expense
InterestExpense
2166000
us-gaap Interest Expense
InterestExpense
1101000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5435000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-73000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4883000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17593000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8310000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29781000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17454000

Files In Submission

Name View Source Status
0000950170-21-001384-index-headers.html Edgar Link pending
0000950170-21-001384-index.html Edgar Link pending
0000950170-21-001384.txt Edgar Link pending
0000950170-21-001384-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sght-20210630.htm Edgar Link pending
sght-20210630.xsd Edgar Link pending
sght-20210630ex31_1.htm Edgar Link pending
sght-20210630ex31_2.htm Edgar Link pending
sght-20210630ex32_1.htm Edgar Link pending
sght-20210630ex32_2.htm Edgar Link pending
sght-20210630_cal.xml Edgar Link unprocessable
sght-20210630_def.xml Edgar Link unprocessable
sght-20210630_htm.xml Edgar Link completed
sght-20210630_lab.xml Edgar Link unprocessable
sght-20210630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending